Position in LGND
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$10,580
+$2,829 QoQ
Shares Held
53
+29.3% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LGND Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Bare Financial Services, Inc holds $191,078 across 74 Biotechnology names. LGND ranks #4 (5.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
218 | $13,668 | |
| 2 | PTCT |
Ptc Therapeutics, Inc.
|
179 | $12,193 | |
| 3 | KRYS |
Krystal Biotech, Inc.
|
47 | $12,139 | |
| 4 | LGND |
Ligand Pharmaceuticals Inc
This page
|
53 | $10,580 | |
| 5 | PTGX |
Protagonist Therapeutics, Inc
|
95 | $10,011 | |
| 6 | TGTX |
Tg Therapeutics, Inc.
|
226 | $7,507 | |
| 7 | ADMA |
Adma Biologics, Inc.
|
831 | $7,485 | |
| 8 | NUVL |
Nuvalent, Inc.
|
60 | $6,146 |
All Filings in LGND
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $10,580 | 53 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $7,751 | 41 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $7,262 | 41 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $1,136 | 10 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $735 | 7 | Shares | Sole | 2025-05-12 | |
| No filing history on record for this holder in this stock. | ||||||